191 related articles for article (PubMed ID: 32049075)
1. Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo.
Shu L; Ren L; Wang Y; Fang T; Ye Z; Han W; Chen C; Wang H
Chem Commun (Camb); 2020 Mar; 56(20):3069-3072. PubMed ID: 32049075
[TBL] [Abstract][Full Text] [Related]
2. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
3. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
4. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
5. [Ru(phen)
Li R; Ma Y; Hu X; Wu W; Wu X; Dong C; Shi S; Lin Y
Dalton Trans; 2020 Jul; 49(26):8864-8871. PubMed ID: 32602487
[TBL] [Abstract][Full Text] [Related]
6. A nuclear permeable Ru(ii)-based photoactivated chemotherapeutic agent towards a series of cancer cells: in vitro and in vivo studies.
Tian N; Feng Y; Sun W; Lu J; Lu S; Yao Y; Li C; Wang X; Zhou Q
Dalton Trans; 2019 May; 48(19):6492-6500. PubMed ID: 30994660
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex.
Soldevila-Barreda JJ; Azmanova M; Pitto-Barry A; Cooper PA; Shnyder SD; Barry NPE
ChemMedChem; 2020 Jun; 15(11):982-987. PubMed ID: 32237195
[TBL] [Abstract][Full Text] [Related]
8. A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).
Ramu V; Gill MR; Jarman PJ; Turton D; Thomas JA; Das A; Smythe C
Chemistry; 2015 Jun; 21(25):9185-97. PubMed ID: 25950156
[TBL] [Abstract][Full Text] [Related]
9. New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules.
Savić A; Marzo T; Scaletti F; Massai L; Bartoli G; Hoogenboom R; Messori L; Van Deun R; Van Hecke K
Biometals; 2019 Feb; 32(1):33-47. PubMed ID: 30367340
[TBL] [Abstract][Full Text] [Related]
10. A Multi-action and Multi-target Ru
Karges J; Yempala T; Tharaud M; Gibson D; Gasser G
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7069-7075. PubMed ID: 32017379
[TBL] [Abstract][Full Text] [Related]
11. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Characterization, and Biological Properties of Steroidal Ruthenium(II) and Iridium(III) Complexes Based on the Androst-16-en-3-ol Framework.
Koch V; Meschkov A; Feuerstein W; Pfeifer J; Fuhr O; Nieger M; Schepers U; Bräse S
Inorg Chem; 2019 Dec; 58(23):15917-15926. PubMed ID: 31714764
[TBL] [Abstract][Full Text] [Related]
13. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
14. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.
Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN
Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901
[TBL] [Abstract][Full Text] [Related]
15. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
16. New organoruthenium compounds with pyrido[2',3':5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action.
Pavlović M; Nikolić S; Gligorijević N; Dojčinović B; Aranđelović S; Grgurić-Šipka S; Radulović S
J Biol Inorg Chem; 2019 Mar; 24(2):297-310. PubMed ID: 30762123
[TBL] [Abstract][Full Text] [Related]
17. A mitochondria-targeting dinuclear Ir-Ru complex as a synergistic photoactivated chemotherapy and photodynamic therapy agent against cisplatin-resistant tumour cells.
Zhang C; Guan R; Liao X; Ouyang C; Rees TW; Liu J; Chen Y; Ji L; Chao H
Chem Commun (Camb); 2019 Oct; 55(83):12547-12550. PubMed ID: 31576841
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors.
Frühauf S; Zeller WJ
Cancer Chemother Pharmacol; 1991; 27(4):301-7. PubMed ID: 1998986
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes.
Engelbrecht Z; Roberts KE; Hussan A; Amenuvor G; Cronjé MJ; Darkwa J; Makhubela BCE; Sitole L
Bioorg Med Chem Lett; 2020 Oct; 30(20):127492. PubMed ID: 32791194
[TBL] [Abstract][Full Text] [Related]
20. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
